Professional
Added to YB: 2026-07-31
Pitch date: 2026-07-29
CDXS [neutral]
Codexis, Inc.
-0.67%
current return
Author Info
Pernas Research is a former CIO of a $3.5B fund that now share actionable stock research. Sign up for the newsletter.
Company Info
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
Market Cap
$133.6M
Pitch Price
$1.49
Price Target
N/A
Dividend
N/A
EV/EBITDA
-9.33
P/E
-4.10
EV/Sales
1.81
Sector
Life Sciences Tools and Services
Category
growth
Pernas Research Passes On: Codexis, Inc.
CDXS (pass): Enzyme maker ($136M mkt cap, $1.5/share) developing ECO Synthesis—cheaper, scalable siRNA drug production. New CEO Moore aims to prove commercial scale & land big pharma/manufacturer partnerships. Recent offering extends runway, but Pernas awaits enterprise traction.
Read full article (1 min)